PDCD1 and neoplasm: Immune checkpoint therapies, such as antibodies targeting programmed cell death protein 1 (PD-1) and programmed death–ligand 1 (PD-L1), prevent tumor cells from evading cytotoxic T cells leading to their clearance by the immune system and have shown efficacy in treating advanced melanoma (2, 3, 4).